Does Dr. Menken study triple-negative breast cancer?

Yes, Dr. Menken specializes in research related to triple-negative breast cancer, particularly focusing on immune cell interactions.

What treatments has Dr. Menken researched?

While her work primarily focuses on prediction markers, understanding immune cell behavior in tumors can influence treatment decisions for breast cancer patients.

Is Dr. Menken's work relevant to breast cancer patients?

Yes, her research provides valuable insights that can help doctors make informed treatment choices for patients with breast cancer, specifically those with the triple-negative subtype.

DR. FAITH A. MENKEN, M.D.

NEW YORK, NY

Research Active

Surgery NPI registered 21+ years 7 publications 1952 – 2018 NPI: 1659376085

Surgery

PrognosisVaginaTriple Negative Breast NeoplasmsSurvival RateCombined Modality TherapyImage Processing, Computer-AssistedGynecologyLymphocytes, Tumor-InfiltratingCarcinoma, Ductal, BreastLightEndoscopyCarcinoma, LobularPhotographyCervix UteriLighting

Practice Location

184 E. 70TH STREET
NEW YORK, NY 10021

Phone: (212) 439-9547

What does FAITH MENKEN research?

Dr. Menken studies triple-negative breast cancer, a subtype of breast cancer that does not have three common receptor types known to fuel most breast cancer growth. She particularly looks at a type of immune cell known as CD8 tumor-infiltrating lymphocytes (TILs) and how their presence in tumors can indicate a patient's chances of survival after treatment. By using digital image analysis, her work evaluates whether counting these immune cells in concentrated areas or 'hot spots' of the tumor provides valuable insights for prognosis, potentially improving the decision-making process for doctors and patients.

Key findings

Counting CD8 tumor-infiltrating lymphocytes in hot spots of tumors is as effective as counting them throughout the entire tumor in predicting survival outcomes for patients with triple-negative breast cancer.
A specific size of hot spot indicated a significant link to overall survival rates, offering a new tool for assessing patient prognosis after treatment.
The study highlights that small areas of concentrated immune cells can be just as telling about a patient's future health as larger, more extensive measurements.

Frequently asked questions

Does Dr. Menken study triple-negative breast cancer?: Yes, Dr. Menken specializes in research related to triple-negative breast cancer, particularly focusing on immune cell interactions.
What treatments has Dr. Menken researched?: While her work primarily focuses on prediction markers, understanding immune cell behavior in tumors can influence treatment decisions for breast cancer patients.
Is Dr. Menken's work relevant to breast cancer patients?: Yes, her research provides valuable insights that can help doctors make informed treatment choices for patients with breast cancer, specifically those with the triple-negative subtype.

Publications in plain English

Hot Spot and Whole-Tumor Enumeration of CD8Tumor-Infiltrating Lymphocytes Utilizing Digital Image Analysis Is Prognostic in Triple-Negative Breast Cancer.

2018

Clinical breast cancer

McIntire PJ, Irshaid L, Liu Y, Chen Z, Menken F +3 more

Plain English
This study examined the presence of a type of immune cell, called CD8 tumor-infiltrating lymphocytes (TILs), in triple-negative breast cancer to see how it might help predict patient outcomes. Researchers found that counting these immune cells in small "hot spots" within the tumor is just as useful for predicting survival as counting them throughout the entire tumor. For example, a specific size of hot spot showed a significant link to overall survival, indicating its potential to help doctors gauge how well a patient might do after treatment. Who this helps: This helps patients with triple-negative breast cancer and their doctors in making more informed treatment decisions.

PubMed